Contrasting NeuroMetrix (NURO) and Antares Pharma (ATRS)

NeuroMetrix (NASDAQ: NURO) and Antares Pharma (NASDAQ:ATRS) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, earnings, institutional ownership, profitability, risk and dividends.

Valuation and Earnings

This table compares NeuroMetrix and Antares Pharma’s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
NeuroMetrix $15.72 million 0.22 -$13.27 million ($20.01) -0.09
Antares Pharma $53.10 million 11.66 -$15.90 million ($0.12) -33.00

NeuroMetrix has higher revenue, but lower earnings than Antares Pharma. Antares Pharma is trading at a lower price-to-earnings ratio than NeuroMetrix, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

6.5% of NeuroMetrix shares are owned by institutional investors. Comparatively, 36.8% of Antares Pharma shares are owned by institutional investors. 4.4% of NeuroMetrix shares are owned by company insiders. Comparatively, 11.6% of Antares Pharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Risk & Volatility

NeuroMetrix has a beta of 0.41, indicating that its stock price is 59% less volatile than the S&P 500. Comparatively, Antares Pharma has a beta of 0.44, indicating that its stock price is 56% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings and price targets for NeuroMetrix and Antares Pharma, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
NeuroMetrix 0 0 2 0 3.00
Antares Pharma 0 0 3 1 3.25

NeuroMetrix presently has a consensus target price of $26.00, indicating a potential upside of 1,320.77%. Antares Pharma has a consensus target price of $4.58, indicating a potential upside of 15.53%. Given NeuroMetrix’s higher possible upside, research analysts plainly believe NeuroMetrix is more favorable than Antares Pharma.

Profitability

This table compares NeuroMetrix and Antares Pharma’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
NeuroMetrix -83.92% -209.56% -135.03%
Antares Pharma -34.27% -41.37% -25.74%

Summary

Antares Pharma beats NeuroMetrix on 12 of the 14 factors compared between the two stocks.

NeuroMetrix Company Profile

NeuroMetrix, Inc. is a healthcare company combining bioelectrical and digital medicine to address chronic health conditions, including chronic pain, sleep disorders and diabetes. The Company is engaged in the sale of medical equipment, and consumables and accessories. It has two principal product lines: Wearable neuro-stimulation therapeutic devices and Point-of-care neuropathy diagnostic tests. Its products include ADVANCE NCS/EMG System (the ADVANCE System), Quell, SENSUS and DPNCheck. Quell is a wearable device for relief of chronic intractable pain, such as nerve pain due to diabetes and lower back problems. The SENSUS pain therapy device, the technological predecessor to Quell, is a prescription neuro-stimulation device based on transcutaneous electrical nerve stimulation (TENS) for relief of chronic, intractable pain. DPNCheck is a quantitative nerve conduction test. ADVANCE System is a platform for the performance of traditional nerve conduction studies.

Antares Pharma Company Profile

Antares Pharma, Inc. (Antares) is a specialty pharmaceutical company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies. The Company develops, manufactures and commercializes therapeutic products using its drug delivery systems. Its subcutaneous injection technology platforms include VIBEX disposable pressure-assisted auto injector system suitable for branded and generic injectable drugs in unit dose containers, reusable needle-free spring-action injector devices, and disposable multi-use pen injectors for use with cartridges. The Company makes a reusable, needle-free spring action injection device, ZOMA-Jet or Twin-Jector, which is marketed through its partners for use with human growth hormone (hGH). The Company operates through drug delivery segment, which includes self-administered parenteral pharmaceutical products and technologies.

Receive News & Ratings for NeuroMetrix Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeuroMetrix Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply